#3062
The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features
Introduction:
There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Alors-Pérez E
Authors:
Alors-Pérez E,
Pedraza-Arévalo S,
Vázquez-Borrego M,
Blázquez-Encinas R,
Herrera-Martínez A,
Keywords:
PanNET,
CELF4,
splicing,
aggressiveness,
pituitary tumors,
#3053
The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors
Introduction:
Alternative splicing dysregulation is increasingly regarded as a novel cancer hallmark influencing all key tumor features. We have shown that neuroendocrine tumors (NETs) overexpress aberrantly spliced variants of neuropeptides and receptors that increase tumor malignancy. More recently, we discovered that the splicing machinery is dysregulated in pituitary and pancreatic NETs. To date, the status of this machinery in low grade pulmonary NETs is largely unknown.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Blázquez-Encinas R
Authors:
Blázquez-Encinas R,
Caro M,
Pedraza-Arévalo S,
Alors-Pérez E,
Herrera-Martínez A,
Keywords:
low grade pulmonary NETs,
splicing,
splicing machinery,
malignancy,
#3040
Palliative CT Brachytherapy in Hepatic Metastatic NET
Introduction:
Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Jann H
Authors:
Feldhaus F,
Jann H,
Jonczyk M,
Boening G,
Wieners G,
Keywords:
brachytherapy,
afterloading,
hepatic metastases,
local tumor ablation,
local tumor control,
#2964
Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing
Introduction:
High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
La Salvia A
Authors:
La Salvia A,
Espinosa Olarte P,
Modrego Sanchez A,
Riesco Martinez M,
Garcia Carbonero R,
Keywords:
Esophageal neuroendocrine carcinoma,
tumor genome sequencing,
immunotherapy,
tumor burden,
personalized therapy,